Hims & Hers Health (NYSE:HIMS) Trading Down 0.9% – Should You Sell?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) traded down 0.9% on Friday . The company traded as low as $33.22 and last traded at $34.07. 7,643,464 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 13,064,865 shares. The stock had previously closed at $34.39.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HIMS shares. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Citigroup reiterated a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a research report on Thursday. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Price Performance

The firm has a market capitalization of $8.00 billion, a price-to-earnings ratio of 81.85 and a beta of 1.37. The stock has a fifty day moving average of $37.64 and a two-hundred day moving average of $27.53.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $9,319,952.14. This trade represents a 8.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Melissa Baird sold 85,561 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $31.01, for a total value of $2,653,246.61. Following the completion of the transaction, the chief operating officer now directly owns 630,986 shares in the company, valued at $19,566,875.86. This represents a 11.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,062,011 shares of company stock worth $36,892,724. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the period. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.